BOLT Stockholders Should Contact Shareholder Rights Law Firm Robbins LLP for Information About the Class Action Against Bolt Biotherapeutics, Inc.
Bolt BiotherapeuticsBolt Biotherapeutics(US:BOLT) GlobeNewswire News Room·2024-07-23 06:47

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The complaint alleges that on May 14, 2024, Bolt issued a press release announcing that the Company would cease further development of BDC-1001 and focus resources on BDC-3042 and BDC-4182 upon determining that BDC-1001 failed to meet its pre-defined success criteria, that the Company's Chief Executive Officer Randall C. Schatzman and Chief Medical Officer Edith Perez would be moved into advisory roles ...

BOLT Stockholders Should Contact Shareholder Rights Law Firm Robbins LLP for Information About the Class Action Against Bolt Biotherapeutics, Inc. - Reportify